Pfizer Inc, said on Friday, it has agreed to acquire Coley Pharmaceutical Group Inc, a developer of vaccine technology and drugs to treat cancer, asthma and other disorders, for $164 million, reports Reuters from Boston.
   
The companies said shareholders holding about 27 per cent of Coley’s shares have entered into agreements to tender their shares.